Orchid Pharma Q3FY26 Earnings Call Set for Feb 12

Orchid Pharma Limited announces analysts/investors earnings call on February 12, 2026 at 4:30 PM IST to discuss Q3FY26 financial results ended December 31, 2025, hosted by Systematix Institutional Equities.

Orchid Pharma Q2 FY26 Results: Revenue Declines 13% YoY to INR 194 Crores Amid Antibiotics Market Downturn

Orchid Pharma reported quarterly sales of INR 194 crores, down 13% year-on-year, with gross margins compressed to 32% from 43% due to inventory revaluation and weak antibiotic market conditions. The company completed acquisition of global rights to Enmetazobactam (Exblifep) and reported strong domestic performance with 15,000 patients treated and 200,000+ vials sold through its Orblicef brand partnership with Cipla.

Orchid Pharma Reports Delays in QIP-Funded Projects, Revises Fund Allocation

Orchid Pharma Limited submitted its monitoring agency report for the quarter ended September 30, 2025, regarding the utilization of Rs. 400 crore raised through Qualified Institutional Placement. The company revised the allocation of QIP proceeds among project objectives following shareholder approval through AGM resolution dated September 20, 2025. Two key projects face implementation delays: the investment in Orchid BioPharma Limited for setting up manufacturing facility in Jammu, and funding capital expenditure for new API facility block in Alathur, Tamil Nadu, though the extent of delays remains unascertainable. For the Jammu project, Rs. 73.02 crores has been utilized as of September 30, 2025, with land acquisition challenges cited as the primary cause of delay. Registration of 164.50 Kanal out of 203.8 Kanal identified land has been completed, with remaining land registration expected by December 2025. The Alathur project delay is attributed to dependency on the Jammu 7ACA project, with only Rs. 0.36 crores utilized. The company has deployed unutilized proceeds in fixed deposits with Yes Bank Limited. CARE Ratings Limited served as the monitoring agency and reported no deviation from stated objectives.